824 filings
Page 3 of 42
8-K
ubwno2m5
15 Sep 23
Changes in Registrant's Certifying Accountant
4:05pm
UPLOAD
7js a9305lhmvm3i17y
12 Sep 23
Letter from SEC
12:00am
NT 10-Q
eggmxznuj1266
14 Aug 23
Notice of late quarterly filing
4:09pm
ARS
rldu79lc1tq68a37h1
7 Aug 23
Annual report to shareholders
4:09pm
DEFA14A
oo2q2
7 Aug 23
Additional proxy soliciting materials
4:07pm
8-K
lr3jr7l
7 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
upmo17rt
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
15dee
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
o9ck asp2
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
EFFECT
yjxv3ybx79 x5
8 May 23
Notice of effectiveness
12:15am
424B4
dnudmg 85pjug
5 May 23
Prospectus supplement with pricing info
6:43pm
CORRESP
ua7z9rzp3vtffv2yk
4 May 23
Correspondence with SEC
12:00am
8-K
mpsivaufg6
3 May 23
Strengthens regulatory and orphan drug development expertise
5:00pm
8-K
llyumdg o5nwhg6
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am